Written by ι Stock Market Media Group Staff — November 12, 2013
Nuvilex, Inc. (OTCQB: NVLX) announced last week that it has acquired the exclusive worldwide rights to a cellulose-based live-cell encapsulation technology for the development of treatments for diabetes. In order to pull off the acquisition, Nuvilex had to convince investors to part with $1.5 million dollars in cash. One wouldn’t think this a hard sell given the acquisition could lead to a multi-billion dollar treatment for the company. And, you’d be right because not only did the company cull together the cash, but it did so at $0.15, a price above Nuvilex’s current price per share.
Clearly there is a lot of excitement and energy surrounding this acquisition knowing that it gives the small Silver Spring, Maryland, biotech full rights over any type of diabetes treatment, by any entity using this technology. Diabetes is a disease that many pharmaceutical and biotech firms want a treatment for in their pipelines.
Many of these firms need to look no further than Nuvilex’s technology – and for all the reasons Nuvilex made the move. The company’s executives said their decision to make the acquisition stems, in large part, from the results of “proof-of-principle” studies in which cells that produce insulin were transplanted into diabetic animals. The diabetic animals had much higher than normal levels of glucose in their bloodstream and had a difficult time controlling their glucose levels, just as humans with diabetes do.
In animals provided with the encapsulated cells, their blood glucose levels normalized and remained stable for the duration of one six-month study, indicating the encapsulated cells produced insulin in response to their higher than normal blood glucose levels. The cellulose-based capsules seem to have prevented the encapsulated cells from being attacked by the diabetic animals’ immune systems, even in the absence of immunosuppressive drugs. Therefore, the encapsulated cells appear to have acted as an artificial or replacement pancreas.
Essentially creating an “artificial pancreas” can eventually make for a blockbuster headline at Nuvilex after it works its way through further studies and then enters into human clinical trials with the diabetes treatment. That headline will only grow more and more dramatic as the amount spent on diabetes each year balloons. According to the American Diabetes Association, in the U.S. alone, $176 billion is spent annually on medical costs associated with diabetes with over $22 billion of that being spent on treatments for the disease. By 2018, the annual market for diabetes drugs and devices is projected to reach over $114 billion worldwide.
This dramatic rise in costs is directly attributed to the growing number of diabetics being diagnosed worldwide. The International Diabetes Federation estimates that the number of diabetics is expected to climb to 552 million by 2030 if “urgent action” isn’t taken – that’s 1 in every 10 people on the planet! Worse yet, those numbers are estimated to grow to 1 in every 3 people by 2050 at its current pace.
The need is great and only growing greater for urgent action, and now with this acquisition, Nuvilex is prepared to build a pipeline of treatments that should be coveted by others trying to build their own pipeline.